Business
Healthscope hospitals change hands, but not fortunes
The private hospital chain found its latest buyers in the ICU
|
The private hospital chain found its latest buyers in the ICU
Because the CSL chair is so revered, nobody will say the quiet part out loud.
The company is undisputed king of the blood products jungle no longer.
Our greatest biotech export is at the crossroads, or was it just t-boned?
There is more soreness ahead for Australian investors who avoid the US radiology juggernaut.
As the US experience demonstrates, PE and hospitals are a terrible mix.
Phil King's clients are enduring one of their worst ever stints, but Rampart reckons you'd be mad to death-ride him.